Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6485)	6/6/2002 11:03:10 AM
From: Ian@SI	Respond to of 52153

I went out for a run and came back to see that ICOS is now a teenager. Sitting with an approvable letter for CIALIS, this would appear to be a major opportunity. But then I thought the same at $25...

To: Biomaven who wrote (6485)	6/6/2002 11:21:19 AM
From: quidditch	Respond to of 52153

So, Peter, in this winter, spring and (no doubt) summer of our discontent (has any one yet done what the treasurer of El Paso Electric, I think, has done?--no response required), what are you nibbling at here? It would seem, unfortunately, that there is a vast, unending cornucopia of BT offerings on sale at prices that seem to become ever more attractive, with the ironic implication (for those of us who are not heavily into cash) that these fruit sit increasingly beyond our reach. ITMN, SEPR, CRXA, ELN, VPHM, ISIS?? quid

To: Biomaven who wrote (6485)	6/6/2002 3:14:00 PM
From: IRWIN JAMES FRANKEL	Read Replies (3) \| Respond to of 52153

ELN - In valuing ELN how do we figure in the LYON's with the poison put? It just seems that the lower the stock goes the greater the dilution caused by the put. That fact has kept me on the sideline despite thinking that a price of 6 is nuts. ij Disclosure: No position currently